Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 26.1% in December

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totaling 125,539 shares, an increase of 26.1% from the November 30th total of 99,564 shares. Based on an average daily volume of 111,335 shares, the days-to-cover ratio is currently 1.1 days. Currently, 2.6% of the company’s stock are sold short. Currently, 2.6% of the company’s stock are sold short. Based on an average daily volume of 111,335 shares, the days-to-cover ratio is currently 1.1 days.

Evaxion A/S Stock Performance

Evaxion A/S stock opened at $4.78 on Wednesday. Evaxion A/S has a 1 year low of $1.20 and a 1 year high of $12.15. The firm’s 50-day moving average is $5.61 and its 200-day moving average is $4.21. The company has a market cap of $39.87 million, a P/E ratio of -12.26 and a beta of 0.28.

Analysts Set New Price Targets

Several equities analysts have recently commented on EVAX shares. Jones Trading upgraded Evaxion A/S to a “strong-buy” rating in a research note on Wednesday, October 29th. Edward Jones started coverage on shares of Evaxion A/S in a research note on Thursday, October 30th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a report on Monday, October 20th. Lake Street Capital upped their target price on shares of Evaxion A/S from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Tuesday, October 14th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Evaxion A/S has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.